A Novel potential positron emission tomography imaging agent for vesicular monoamine transporter type 2

Abstract

In the early 1990s, 9-(+)-11 C-dihydrotetrabenazine (9-(+)-11 C-DTBZ) was shown to be a useful positron emission tomography (PET) imaging agent for various neurodegenerative disorders. Here, we described the radiosynthesis and evaluation of the 9-(+)-11 C-DTBZ analog, 10-(+)-11 C-DTBZ, as a vesicular monoamine transporter2 (VMAT2) imaging agent and compare it with 9-(+)-11 C-DTBZ. 10-(+)-11 C-DTBZ was obtained by11 C-MeI methylation with its 10 hydroxy precursor in the presence of 5 M NaOH. It had a slightly better average radiochemical yield of 35.3 ± 3.6% (decay-corrected to end of synthesis (EOS)) than did 9-(+)-11 C-DTBZ (30.5 ± 2.3%). MicroPET studies showed that 10-(+)-11 C-DTBZ had a striatum-to-cerebellum ratio of 3.74 ± 0.21 at 40 min post-injection, while the ratio of 9-(+)-11 C-DTBZ was 2.50 ± 0.33. This indicated that 10-(+)-11 C-DTBZ has a higher specific uptake in VMAT2-rich brain regions, and 10-(+)-11 C-DTBZ may be a potential VMAT2 radioligand. Our experiment is the first study of 10-(+)-11 C-DTBZ to include dynamic brain distribution in rat brains.